Indian CRDMOs: Trust and technical execution are becoming the key differentiators, with China+1 impacts potentially becoming clearer around 2027

Overview

This report compiles three expert calls focusing on the evolution of India's CRDMO industry, the potential reallocation of orders driven by China+1, and the technical complexity of peptide/GLP-1 manufacturing. The core conclusion is that Indian suppliers seeking to capture higher-value projects must upgrade from cost advantages to comprehensive competitiveness based on trust, governance, compliance, scientific capabilities, process development, and rapid execution.

Core views

The report believes that the growth logic for Indian CRDMOs is shifting from early-stage chemical FTE outsourcing toward capability-driven platforms able to handle proprietary processes, complex modalities, and late-stage validation projects. Anthem Biosciences emphasizes small-molecule chemistry, flow chemistry, biocatalysis, and ADC linker-payload capabilities; Aragen emphasizes its evolution from a discovery CRO into an integrated “molecules-to-medicines” CRDMO through three major business divisions that enhance execution. China+1 is an important driver, but it is not simply a case of “China down equals India up,” because China retains advantages in reactor scale and biotech licensing. In peptide manufacturing, the GLP-1 opportunity exists, but the ultimate outcome depends on route selection, impurity control, purification, fill-finish, and equipment capabilities.

Analysis framework

The report uses expert interviews and industry-theme synthesis, analyzing company capabilities, customer needs, process routes, technical bottlenecks, and supply-chain reconfiguration within a unified framework. It focuses on comparing Indian CRDMOs with Chinese suppliers across scale, speed, scientific depth, compliance governance, and complex-modality capabilities.

Methodology notes

• industry_analysisChina+1 supply-chain reallocation

  Supply-chain diversification

  Assess whether orders are being reallocated from China to markets such as India by observing large pharmaceutical companies, BioSecure/1260H, WuXi-related concerns, and customers' multi-supplier strategies.

• Competition & strategyCapability-led CRDMO differentiation

  Capability-driven CRDMO differentiation

  Indian companies cannot rely solely on low-cost competition; they need to demonstrate substitutability through scientific capabilities, process development, compliance systems, governance quality, modality coverage, and execution speed.

• manufacturing_processPeptide route selection and purification bottleneck

  Peptide manufacturing route and purification bottlenecks

  Peptide and GLP-1 manufacturing requires early selection among SPPS, LPPS, and hybrid routes, as well as solutions to key bottlenecks involving coupling, acylation, enzymatic cleavage, impurity control, and reverse-phase chromatography purification.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Indian CRDMO industry

  Core beneficiary direction

  Strengths

  Chemical foundations, a favorable cost position, English-language and outsourcing-service experience, and a gradually strengthening foundation of IP trust.

  Weaknesses

  Still behind leading Chinese companies in reactor scale, biological capabilities, complex-modality validation, and the depth of certain supply chains.

  Comparison

  Compared with China, India is less able to compete on scale; the report views a more realistic path as winning through agility, technical differentiation, green chemistry, and rapid execution.

  Risks

  China+1 transfers falling short of expectations, failed customer audits, and cost advantages being offset by quality and efficiency requirements.

• Anthem Biosciences

  Expert-interview company and capability sample

  Strengths

  Emphasizes process development, flow chemistry, biocatalysis, linker-payloads, high-potency handling, advanced analytics, and rapid problem-solving.

  Weaknesses

  Cannot easily match the reactor scale of Chinese leaders such as WuXi.

  Comparison

  Pursues a technically agile strategy rather than pure scale competition.

  Risks

  Route changes require customer approval, while validation of complex projects and late-stage commercial execution remain areas to monitor.

• Aragen Life Sciences

  Expert-interview company and platform sample

  Strengths

  Evolved from GVK Bio into a “molecules-to-medicines” platform covering discovery, development & manufacturing, and biologics, with relationships with large pharmaceutical companies and improving cross-selling.

  Weaknesses

  Weak biotech financing previously created pressure, and a customer may not necessarily remain with the same service provider throughout the full lifecycle of a single molecule.

  Comparison

  Compared with a standalone CRO, it places greater emphasis on cross-stage services and increasing share of wallet.

  Risks

  Customer-switching pace, pricing pressure, validation of complex-modality capabilities, and large-scale manufacturing execution.

• Peptide / GLP-1 manufacturing chain

  High-growth but high-barrier opportunity

  Strengths

  GLP-1 demand and the Indian market opportunity exist; companies with fermentation, chemical coupling, purification, and drug-delivery capabilities may have advantages.

  Weaknesses

  Long-chain or modified peptides create challenges involving impurities, purification, yield, solvent consumption, and route selection.

  Comparison

  Unlike ton-scale insulin production, GLP-1 drug substance is produced at approximately kilogram scale and cannot simply be compared with bulk API capacity.

  Risks

  Reverse-phase chromatography bottlenecks, slow injectable adoption, side effects, inventory accumulation, and insufficient equipment/fill-finish capabilities.

• Chinese CRDMOs / WuXi-related supply chain

  Primary competitive and reconfiguration reference

  Strengths

  Chinese leaders possess advantages in scale, productivity, reactor capabilities, and the biotech licensing ecosystem.

  Weaknesses

  BioSecure/1260H and geopolitical concerns could encourage customer diversification.

  Comparison

  India's opportunity comes from substitution and diversification, not linear replacement of China.

  Risks

  The Chinese ecosystem is resilient; if India's absorption capacity is insufficient, order transfers may fall below market expectations.

Key data

• China+1 visibility timelineAround 2027Aragen believes that BioSecure/1260H and WuXi-related concerns could accelerate transfers, but the impact of customer switching may not become clearer until around 2027.
• Flow-chemistry caseApproximately 5-ton production reduced from about 3.5 months to approximately 35 daysAnthem used the transition from batch to a flow setup in a nitration process to illustrate the impact of process development on cycle time, safety, and controllability.
• Aragen historical growthFY18–FY25 revenue CAGR of approximately 16%, EBITDA CAGR of approximately 20%, and PAT CAGR of approximately 18%Management-cited data used to illustrate Aragen's expansion from a discovery CRO into a broader CRDMO platform.
• Aragen cross-sellingApproximately 50% of revenue comes from customers using both discovery and manufacturing servicesUp from approximately 40% four years ago, indicating increased cross-stage services and customer stickiness.
• Indian GLP-1 opportunityApproximately US$300–500mnExperts believe the opportunity is real, but adoption in India remains at an early stage and injectable treatments face behavioral barriers.
• Indian insulin marketApproximately Rs50bnThe report also points out that GLP-1 growth does not mean insulin demand will disappear.
• Liraglutide synthesis exampleA 10L fermentation starting material with 99.1% purity ultimately produced 3.7g of peptide APIUsed to illustrate the challenges of yield, purification, and impurity control in peptide API manufacturing.
• Peptide capability-building periodApproximately 5–10 yearsExperts said that building capabilities from fragment manufacturing to API-grade peptide manufacturing may require a lengthy accumulation period.

Impact & implications

The implication for investment decisions is that the medium- to long-term opportunity in Indian CRDMOs is more about structural upgrading than short-term capacity-expansion trades. Beneficiaries should be companies able to demonstrate IP credibility, complex chemistry, ADC/peptide capabilities, regulatory reliability, cross-stage customer stickiness, and execution speed. Risks include slower-than-expected customer transfers, continued Chinese competitiveness, high technical barriers in peptide manufacturing, and margin pressure on Indian companies relying solely on price competition.

Risks

• China+1 order transfers may proceed more slowly than the market expects, with greater clarity potentially emerging only around 2027.
• China's biotech out-licensing capabilities and CRDMO scale advantages may continue to weaken the Indian substitution thesis.
• If Indian CRDMOs rely solely on low costs without achieving Chinese-style productivity, they may face margin pressure.
• Peptide/GLP-1 manufacturing faces bottlenecks involving route selection, coupling, impurity control, and reverse-phase chromatography purification.
• Complex modalities such as ADCs, oligos, and peptide-drug conjugates require late-stage projects and commercial validation.
• A weak biotech financing cycle may affect demand for early-stage R&D outsourcing.
• Slower adoption of injectables in India means GLP-1 demand release may be constrained by behavioral factors and administration convenience.

What to watch

• Whether large pharmaceutical companies continue transferring proprietary processes and higher-value projects to Indian CRDMOs.
• Whether BioSecure/1260H and WuXi-related events lead to more visible supply-chain migration around 2027.
• Real project validation by Indian companies in flow chemistry, biocatalysis, ADC linker-payloads, high-potency handling, and complex analytics.
• Customer audit results, preferred-partner status, repeat orders, and the proportion of revenue from cross-service lines.
• Whether SPPS, LPPS, and hybrid route selection reduces rework, impurities, and costs in peptide manufacturing.
• Progress in building reverse-phase chromatography purification, fill-finish, pen assembly, and delivery-device capabilities.
• GLP-1 inventories, side effects, Indian acceptance of injectables, and the resilience of insulin demand.
• Whether AI and digital tools genuinely improve route recommendations, manufacturability assessments, screening, and process optimization rather than remaining at the conceptual stage.